Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 7Active not recruiting 4Completed 3Terminated 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Plasma cell 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Squamous Cell Carcinoma of Head and Neck 1Pain, Postoperative 1Pain 1Ovarian Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Burkitt Lymphoma 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Acetaminophen × 90 days × Clear all
NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT06788912 2026-06-01

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06992427 2026-05-11

HOPE

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
228 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06043323 2026-05-06

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular

NCT03823534 2026-04-22

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

St. Louis University

Phase 3 Recruiting
60 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Pain, Pain, Postoperative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡